Open AccessHepatic Hemangioendothelioma: An update
Author(s) -
Mayur Virarkar,
Mohammed Saleh,
Radwan Diab,
Melissa W. Taggart,
Peeyush Bhargava,
Priya Bhosale
Publication year - 2020
Publication title -
world journal of gastrointestinal oncology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v12.i3.248
Subject(s) - medicine , magnetic resonance imaging , radiology , epithelioid hemangioendothelioma , hepatocellular carcinoma , positron emission tomography , angiosarcoma , pathology , immunohistochemistry
Primary epithelioid hemangioendotheliomas of the liver (EHL) are rare tumors with a low incidence. The molecular background of EHL is still under investigation, with WWTR1-CAMPTA1 mutation may function as a tumor marker. Commonly, this tumor is misdiagnosed with angiosarcoma, cholangiocarcinomas, metastatic carcinoma, and hepatocellular carcinoma (sclerosing variant). Characteristic features on imaging modalities such as ultrasound, computed tomography, magnetic resonance imaging and positron emission tomography/computed tomography guide in diagnosis and staging. The "halo sign" and the "lollipop sign" on computed tomography and magnetic resonance imaging are described in the literature. Currently, there are no standardized guidelines for treating EHL with treatment options are broad including: chemotherapy, ablation, surgery and liver transplantation with inconsistent results.